Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Dr Reddy's shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1 (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. If side effects from Revlimid become difficult to ...

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...

The trial evaluated the efficacy and safety of the combination of Incyte’s Monjuvi (tafasitamab), Bristol Myers Squibb’s (BMS’s) Revlimid (lenalidomide), and Biogen’s Rituxan (rituximab ...